TIDMMTPH
RNS Number : 4491I
Midatech Pharma PLC
11 December 2020
11 December 2020
Midatech Pharma PLC
("Midatech" or the "Company")
MTX110 Programmes to be Presented
at
The International Symposium on Pediatric Neuro-Oncology,
Karuizawa, Japan (ISPNO 2020)
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D
biotechnology company focused on improving the bio-delivery and
biodistribution of medicines, is pleased to announce that its
University collaborators will be presenting three sets of research
findings on MTX110 at The International Symposium on Pediatric
Neuro-Oncology on 13-16 December 2020 in Karuizawa, Japan (to be
held online this year). The first two presentations, by Columbia
University Medical Center and University of Texas Health Center at
Houston, are being presented for the first time. The third
presentation, by the Pacific Pediatric Neuro-Oncology Consortium,
was also presented at last months' Society of Neuro-Oncology
(SNO2020) conference. Abstract details and links to the posters are
provided below:
1. A Phase I Study Examining the Feasibility of Intermittent
Convection-Enhanced Delivery (CED) of MTX110 for the Treatment of
Children with Newly Diagnosed Diffuse Intrinsic Midline Gliomas
(ABSTRACT DDEL-07, Page iii284*) - Lead Author: Dr Stergios
Zacharoulis MD, Columbia University Medical Center, New York, USA.
In the study:
-- Patients are receiving continuous CED infusions of MTX110 for
48 hours on two cycles separated by 5 to 7 days;
-- 3 patients have been treated so far at 30 microM;
-- No Serious Adverse Events;
-- Toxicity: Grade II diplopia (1) Grade I sensation (n=1), headache Grade II (n=2); and
-- 1 patient progressed 8 months post treatment
The presentation may be found at:
https://www.midatechpharma.com/media/pages/news/a-phase-i-study-examining-the-feasibility-of-intermittent-convection-enhanced-delivery-ced-of-mtx110-for-the-treatment-of-childr/b4b8cf89e6-1607680894/mtx110-203_dipg_trial_-dr_stergio_zacharoulis.pdf
2. High Dose MTX110 (Soluble Panobinostat) Safely Administered
into the Fourth Ventricle in a Non-Human Primate Model (ABSTRACT
DDEL-09, Page iii285*) - Lead Author: Dr David Sandberg MD,
McGovern Medical School, University of Texas Health Center at
Houston, Houston, Texas, USA. Conclusions of the presentation
are:
-- Fourth ventricle catheters were successfully instilled to
enable locoregional infusion of MTX110;
-- MTX110 was well-tolerated, with no evidence of toxicity;
-- Drug levels in the CNS reached a therapeutic range; and
-- The data support the safety of administration of MTX110 via the fourth ventricle
-- Clinical trial in recurrent medulloblastoma patients is ongoing (NCT04315064)
The presentation may be found at:
https://www.midatechpharma.com/media/pages/news/high-dose-mtx110-soluble-panobinostat-safely-administered-into-the-fourth-ventricle-in-a-non-human-primate-model/df48e55757-1607683538/mtx110_preclinical_safety_-dr_david_sandberg.pdf
3. PNOC015: An Open Label Single Arm Phase I/II Study of MTX110
Delivered by Convection-Enhanced Delivery (CED) in Patients with
Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated with
External Beam Radiation Therapy (ABSTRACT EPCT-12, Page
iii306*)
Lead Author: Dr Sabine Mueller, Pacific Pediatric Neuro-Oncology
Consortium
The presentation may be found at:
https://www.midatechpharma.com/media/pages/news/1pnoc015-an-open-label-single-arm-study-of-mtx110-delivered-by-convection-enhanced-delivery-ced-in-patients-with-diffuse-intrins/ee47f281a6-1607683490/mtx110-201_dipg_trial_-dr_sabine_mueller.pdf
* Abstracts from the 19(th) International Symposium on Pediatric
Neuro-Oncology (ISPNO 2020), December 13-16, 2020. Neuro-Oncology,
Volume 22, Supplement 3 may be found at:
http://ispno2020.umin.jp/abstract/files/20201209%20_abstract_supplement_OUP.pdf
Commenting, Steve Damment, EVP R&D of Midatech, said: "These
presentations by Midatech's University collaborators provide useful
data points for our MTX110 programmes; the Columbia study in DIPG
uses an implantable and programmable pump to infuse drug without
the need for repeated surgery, unlike the system deployed in the
UCSF study we recently reported; and, the Texas pre-clinical safety
study demonstrates the feasibility of fourth ventricle infusion,
the method of administration for our ongoing Phase I pilot study in
recurrent medulloblastoma patients."
About MTX110
MTX110 is a water-soluble form of panobinostat free base,
achieved through complexation with
hydroxypropyl-<BETA>-cyclodextrin (HPBCD), that enables
convection-enhanced delivery (CED) at potentially chemotherapeutic
doses directly to the site of the tumour. Panobinostat is a
hydroxamic acid and acts as a non-selective histone deacetylase
inhibitor (pan-HDAC inhibitor). The currently available oral
formulation of panobinostat lactate (Farydak(R)) is not suitable
for treatment of brain cancers owing to poor blood-brain barrier
penetration and inadequate brain drug concentrations. Based on
favourable translational science data, MTX110 is being evaluated
clinically as a treatment for DIPG (NCT03566199, NCT04264143) and
recurrent medulloblastoma (NCT04315064), and preclinically for
treatment of glioblastoma (SNO 2020 Abstract TMOD-27). MTX110 is
delivered directly into and around the patient's tumour via a
catheter system (e.g. CED or fourth ventricle infusions) to bypass
the blood-brain barrier. This technique exposes the tumour to very
high drug concentrations while simultaneously minimising systemic
drug levels and the potential for toxicity and other side effects.
Panobinostat has demonstrated high potency against DIPG tumour
cells in in vitro and in vivo models, and in a key study it was the
most promising of 83 anticancer agents tested in 14 patient-derived
DIPG cell lines (Grasso et al, 2015. Nature Medicine 21(6),
555-559).
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014 (MAR).
For more information, please contact:
Midatech Pharma PLC
Stephen Stamp, CEO, CFO
Steve Damment, EVP R&D
Tel: +44 (0)29 20480 180
www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated Adviser and Joint
Broker)
Freddy Crossley, Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
Tel: +44 (0)20 7886 2500
Turner Pope Investments (TPI) Limited (Joint Broker)
Andrew Thacker (Corporate Broking)
Tel: +44 (0)20 3657 0050
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Edison Group (US Investor Relations)
Megan Paul
Tel: +1 (646) 653 7034
Email: mpaul@edisongroup.com
About Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ:
MTP) is a drug delivery technology company focused on improving
the bio-delivery and bio-distribution of medicines. The Company
combines approved and development medications with its proprietary
and innovative drug delivery technologies to provide compelling
products that have the potential to powerfully impact the lives
of patients.
The Company has developed three in-house technology platforms,
each with its own unique mechanism to improve delivery of medications
to sites of disease. All of the Company's technologies have successfully
entered human use in the clinic, providing important validation
of the potential for each platform:
* Q-Sphera(TM) platform: a disruptive micro-technology
used for sustained release to prolong and control the
release of therapeutics over an extended period of
time (from weeks to months).
* MidaSolve(TM) platform: an innovative nanotechnology
used to dissolve insoluble drugs so that they can be
administered in liquid form directly and locally into
tumours.
* MidaCore(TM) platform: a leading-edge nanotechnology
used for targeting medications to sites of disease.
The platform nature of the technologies offers the potential to
develop multiple drug assets rather than being reliant on a limited
number of programmes. Midatech's technologies are supported by
36 patent families including 120 granted patents and an additional
70 patent applications. Midatech's headquarters and R&D facility
is in Cardiff, UK. For more information please visit www.midatechpharma.com
Forward-Looking Statements
Certain statements in this press release may constitute
"forward-looking statements" within the meaning of legislation in
the United Kingdom and/or United States Private Securities
Litigation Reform Act. All statements contained in this press
release that do not relate to matters of historical fact should be
considered forward-looking statements.
Reference should be made to those documents that Midatech shall
file from time to time or announcements that may be made by
Midatech in accordance with the London Stock Exchange AIM Rules for
Companies ("AIM Rules"), the Disclosure and Transparency Rules
("DTRs") and the rules and regulations promulgated by the US
Securities and Exchange Commission, which contains and identifies
other important factors that could cause actual results to differ
materially from those contained in any projections or
forward-looking statements. These forward-looking statements speak
only as of the date of this announcement. All subsequent written
and oral forward-looking statements by or concerning Midatech are
expressly qualified in their entirety by the cautionary statements
above. Except as may be required under the AIM Rules or the DTRs or
by relevant law in the United Kingdom or the United States,
Midatech does not undertake any obligation to publicly update or
revise any forward-looking statements because of new information,
future events or otherwise arising.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBLBDDDUBDGGB
(END) Dow Jones Newswires
December 11, 2020 12:00 ET (17:00 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From May 2023 to May 2024